Wall Street Bullish on BeOne Medicines AG (ONC) amid Robust Pipeline Development

BeOne Medicines AG (NASDAQ:ONC) is one of the best healthcare stocks to buy for 2026. On January 13, at the 44th Annual J.P. Morgan Healthcare Conference, BeOne Medicines AG (NASDAQ:ONC) reiterated significant progress in its pipeline development.

BRUKINSA, a tyrosine kinase inhibitor, has achieved 74% six-year progression-free survival, compared with 32% with bendamustine plus rituximab, in treatment-naïve chronic lymphocytic leukemia. Sonrotoclax, its BCL2 inhibitor, has received regulatory approval, with an overall response rate of 86% in heavily pretreated CLL patients. The company is also advancing 15 new molecular entities into clinical trials and plans to deliver 8 to 10 additional candidates.

Earlier on January 7, Citizens reiterated a Market Perform rating and a $396 price target on the stock, impressed by robust efficacy data from the company’s phase 3 trial in gastric cancer patients. The expected approval of sonrotoclax, a next-generation BCL2 inhibitor, is also expected to trigger additional approval globally. Likewise, the research firm expects the company’s Brukinsa drug to generate $3.8 billion in 2025.

BeOne Medicines AG (NASDAQ:ONC) is a biotechnology company focused on discovering, developing, and commercializing innovative, affordable oncology treatments. It is known for products such as Brukinsa and Tevimbra and utilizes a worldwide network for R&D and manufacturing.

While we acknowledge the potential of ONC as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 12 Best Consumer Goods Stocks Billionaires Are Quietly Buying and Goldman Sachs Penny Stocks: Top 12 Stock Picks. Disclosure: None. This article is originally published at Insider Monkey.